Three of Boston Scientific‘s newest heart defibrillators have received the European CE Mark of approval.
The Incepta, Energen and Punctua cardiac defibrillators are used for pacing and to manage heart failure.
The products have been tested in Germany, Austria and the Netherlands. Boston Scientific hopes for full commercial launch of the products in the United States and across Europe in the first half of next year.
The company swung to a $190 million profit in the third quarter, a drastic turnaround from the $90 million loss the company reported during the same period last year. Revenue for the quarter was $1.9 billion, a 5 percent decrease.
